Cancer NetworkOriginal article
<![CDATA[Azacitidine/Venetoclax Boosts Event-Free Survival in Induction-Eligible AML]]>
Phase 2positiveAzacitidine/VenetoclaxPositive
AI Analysis
Summary
Phase 2 PARADIGM trial data showed that azacitidine/venetoclax improved event-free survival in induction-eligible acute myeloid leukemia patients, potentially supporting the use of less toxic treatment options.
Clinical Trial Data
Phase
2
Primary Endpoint
Met
Outcome Details
Boosted event-free survival in induction-eligible AML
Importance:6/10
Sentiment:
0.70
Phase 2AMLClinical TrialHematologic Malignancy
Read the original article
Published by Cancer Network on September 8, 2026 2:00 PM